Thrombectomy Devices Market size is poised to expand at 7.3% CAGR from 2023 to 2032, driven by the ongoing technological advancements along with the rising development of minimally invasive and efficient devices.

The growing healthcare expenditure worldwide coupled with the increasing adoption of advanced medical technologies is facilitating the rising investments in latest and most effective treatment options by healthcare facilities. Additionally, with the strong focus on enhancing patient care and outcomes, healthcare institutions are allocating significant resources to procure the latest thrombectomy devices, further fostering the market expansion.

The thrombectomy devices industry is segmented into product type, application, end-use, and region.

Based on product type, the market size from the clot extraction catheter segment is projected to gain significant traction between 2023 and 2032. The growth can be attributed to the strong ability of clot extraction catheters to provide effective and minimally invasive clot removal solutions for facilitating precise and efficient thrombus extraction in various cardiovascular and neurovascular applications.

Additionally, the rising technological advancements for enabling enhanced navigation and maneuverability will contribute to the segment growth. For instance, in June 2023, Penumbra received FDA approval for the launch of its Lightning Bolt 7 arterial thrombectomy system deployed with regulated aspiration to remove blood clots with pressure sensors.

Thrombectomy devices market is anticipated to witness traction from the neurovascular thrombectomy application segment between 2023 and 2032. This is attributed to the rising prevalence of neurovascular conditions, such as ischemic strokes and aneurysms. With the increasing focus on improving the efficacy of neurovascular treatments and reducing associated risks, there is surging demand for advanced thrombectomy devices for adoption in intricate neurovascular procedures. This is likely to propel the segment growth.

Regionally, Europe thrombectomy devices industry will record robust growth through 2032 driven by the increasing healthcare expenditure and the rising incidence of cardiovascular diseases. According to the WHO report, every year across the EU, more than 6 million cases of CVD are identified, and over 1.7 million people die from circulatory system disorders, accounting for around 37% of all fatalities. The strong emphasis on technological advancements and the adoption of innovative medical devices are facilitating the widespread integration of thrombectomy procedures in clinical settings. Moreover, supportive regulatory frameworks and favorable reimbursement policies are also encouraging the adoption of thrombectomy devices across European countries.